Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Subjects
In brief
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.
Key facts
- Study ID
- NCT00783341
- Run by
- Wyeth is now a wholly owned subsidiary of Pfizer
- People needed
- 25
- Starts
- 2008-11-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2009-07-17
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.